Table 2.
Characteristics of first and second allogeneic HCT.
| First HCT | n |
| Disease Status | |
| Remission (chronic phase, n=3) | 78 |
| Relapse/persistent disease (accelerated phase, n=1) | 35 |
| Unknown | 13 |
| Conditioning: | |
| CY, TBI (≥ 12 Gy; + ATG, n=1; + RIT, n=2; + FLU, n=5; + TEPA, n=2; + VP-16, n=2) | 56 |
| BU, CY (+ ATG, n=4; + RIT, n=2; CY, BU, n=1) | 34 |
| TREO, FLU (+ TBI 2 Gy, n=5) | 6 |
| TBI (2–3 Gy; + FLU, n=10; + CY + FLU, n=2; + FLU + RIT, n=1) | 16 |
| BU, FLU | 5 |
| Othera | 9 |
| Donor | |
| HLA-Identical, related (single HLA-antigen mismatched, n=2) | 66 |
| HLA-matched, unrelated (single HLA-allele mismatched, n=5; UCB, n=2) | 42 |
| HLA-mismatched, unrelated | 7 |
| HLA-mismatched, UCB | 9 |
| HLA-haploidentical, related | 2 |
| Stem Cell Source | |
| PBSC | 62 |
| Marrow | 53 |
| UCB | 11 |
| Second HCT | n |
| Disease Status | |
| Remission | 85 |
| Relapse/persistent disease (accelerated phase, n=2; blast crisis, n=2) | 41 |
| HCT-CI | |
| 0,1 | 36 |
| 2,3 | 43 |
| 4 to 9 | 47 |
| Conditioning | |
| TBI (2–4.5 Gy; + FLU, n=40; + CLO, n=4; + FLU + RIT, n=3) | 51 |
| TREO, FLU (+ TBI 2 Gy, n=16) | 25 |
| CY, TBI (≥ 12 Gy; + FLU, n=3) | 16 |
| CY, FLU, TBI (2–4 Gy; + RIT, n=4; +ATG, n=1) | 16 |
| BU, CY (Cy, BU, n=1) | 8 |
| Otherb | 10 |
| Donor | |
| HLA-Identical, related (single HLA-antigen mismatched, n=2) | 27 |
| HLA-matched, unrelated (single HLA-allele mismatched, n=3; double UCB, n=1) | 59 |
| HLA-mismatched, unrelated | 9 |
| HLA-mismatched, UCB | 20 |
| HLA-haploidentical, related | 11 |
| Same | 17 |
| Different | 109 |
| Stem Cell Source | |
| PBSC | 85 |
| Marrow | 20 |
| UCB | 21 |
| Median time between HCTs (range) in months | 23 (2 to 186) |
| Remission duration after 1st HCT (range) in months | 11 (0.7 to 180) |
a
Other: CLO, MEL, THIO, n=1; CY, FLU, n=1; FLU, MEL, n=2; FLU, MEL, THIO, n=1; TLI, ATG, n=1; Samarium, n=1; Unknown, n=1; FLU, TBI (450), n=1.
b
Other: BU, CLO, n=2; BU, FLU, n=3; BU, TEPA, n=2; CY, TEPA, FLU, TBI 4 Gy, n=2; FLU, TBI 8 Gy, n=1
ATG, anti thymocyte globulin; BU, busulfan; CLO, clofarabine; CY, cyclophosphamide; FLU, fludarabine; HCT-CI, HCT–specific comorbidity index; HLA, human leukocyte antigen; PBSC, peripheral blood stem cells; RIT, radioimmunotherapy; TBI, total body irradiation; TEPA, thiotepa; TREO, treosulfan; UCB, umbilical cord blood; VP-16, etoposide.